Clinical Trial

A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-1180 after single- and multiple-ascending doses in healthy subjects.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-10-01 -> 2027-04-01 2026-04-15
minor Completion pushed: 2026-12-01 -> 2027-06-01 2026-04-15
Trial Details
NCT Number NCT07300189
Lead Sponsor OrsoBio, Inc
Conditions Healthy Participants
Enrollment 288 participants
Start Date 2025-10-20
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-14